Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners

Novartis' Phase 3 HARBOR trial for del-desiran in myotonic dystrophy type 1 missed its primary endpoint, following Friday's failure of the Phase 3 pelacarsen Lp(a)HORIZON cardiovascular-outcomes trial. The setbacks raise concerns over assets acquired through Novartis' $12 billion Avidity Biosciences deal and its licensed pelacarsen program, despite pelacarsen lowering Lp(a) levels. In premarket trading, Novartis fell 12.57% to $139.88, while partner Ionis declined 9.80% and Royalty Pharma dropped 6.29%.

Analysis

The key market consequence is not the lost revenue from either program alone, but a reset in Novartis’s capital-allocation credibility. A $12B platform acquisition now has one asset with a pivotal failure before the other programs have established registrational validation; investors should raise both probability-adjusted development costs and impairment risk. Over the next 1-3 months, the relevant question is whether management narrows the neuromuscular portfolio or commits further capital to post-hoc subgroup analyses, which would extend the valuation overhang.

IONS is more exposed to a reassessment of antisense cardiovascular optionality than to an immediate earnings hole, since the failed asset had been embedded in a broader pipeline valuation. The more consequential read-through is that biomarker reduction has again failed to translate into outcomes on top of modern standard-of-care, increasing the evidentiary bar for other cardiometabolic RNA programs. This should favor companies with hard clinical-outcome data over platform narratives during the next two quarters.

RPRX’s selloff may be mechanically larger than its fundamental loss if investors are capitalizing an uncertain royalty stream at full value. Its diversified royalty portfolio limits direct cash-flow damage, but the market needs disclosure on remaining contingent consideration, expected royalty duration, and portfolio NAV sensitivity before treating the decline as an entry point. BIIB has no direct pelacarsen exposure; any sympathetic weakness would be an opportunity rather than a fundamental read-through.

Contrarian risk: NVS may be closer to a tradable bottom than IONS because its diversified base business can absorb a pipeline write-down, whereas IONS still carries higher duration and platform-value sensitivity. A credible FDA path for del-zota or positive del-brax regulatory feedback could quickly re-rate the acquired neuromuscular franchise, so remaining short NVS after the initial gap has unfavorable catalyst asymmetry.

Key Decisions for Investors

• Do not chase the initial NVS decline. Use a 1-3 month short only on a rebound toward the pre-event range if management maintains prior neuromuscular revenue expectations without quantifying incremental trial spend; cover on an FDA-supported del-zota approval path or explicit portfolio restructuring.
• Maintain/establish an IONS underweight versus large-cap biotech (short IONS / long XBI) over 3-6 months. The trade expresses multiple compression from reduced cardiovascular pipeline optionality rather than near-term revenue loss; invalidate if IONS provides a quantified, immaterial pelacarsen valuation impact and delivers positive pivotal data from another late-stage asset.
• Put RPRX on a conditional long watchlist, not an immediate buy. Initiate only if management quantifies pelacarsen NAV exposure at less than roughly 3-4% of enterprise value and confirms no material remaining milestone obligation; target a 6-12 month normalization as diversified royalty cash flows dominate, with downside protection below the post-event low.
• Favor BIIB over IONS as a relative-value biotech pair for the next quarter (long BIIB / short IONS), sized market-neutral. BIIB’s royalty relationship does not create pelacarsen earnings exposure, while IONS faces direct collaboration-value and platform-sentiment pressure; exit if the pair moves 10% against entry or if IONS receives a material non-pelacarsen regulatory catalyst.